VivoSeq
Gastroenterology

Eosinophilic Gastritis

4

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Eosinophilic Gastritis is an early-stage landscape with 4 programs across 2 companies. The most active players are AstraZeneca, Regeneron. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

75/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 3Regeneron logo

Regeneron

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

AK002

Allakos Inc.

Phase 32

Benralizumab

AstraZeneca

Lirentelimab

Allakos Inc.

Approved
No programs

Analysis

Modality Breakdown

75%

Monoclonal antibody

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSSmall molecule125%

Monoclonal antibody leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

9

clinical trials

Completed6 · 67%
Withdrawn1 · 11%
Terminated1 · 11%
Active, not recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
Active, not recruiting·Regeneron logoRegeneron·Phase 2·NCT05831176·22 enrolled
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Completed·AAllakos Inc.·Phase 2·NCT03664960·58 enrolled
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Completed·AAllakos Inc.·Phase 2·NCT03496571·65 enrolled
An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Completed·AAllakos Inc.·Phase 3·NCT04620811·159 enrolled
Dupilumab in Eosinophilic Gastritis
Completed·—·Phase 2·NCT03678545·41 enrolled
Benralizumab for Eosinophilic Gastritis (BEGS)
Completed·—·Phase 2/3·NCT03473977·26 enrolled
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Completed·AAllakos Inc.·Phase 3·NCT04322604·181 enrolled
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
Terminated·AstraZeneca logoAstraZeneca·Phase 3·NCT05251909·12 enrolled
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Withdrawn·AAllakos Inc.·Phase 3·NCT05152563

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)